Provided by Tiger Fintech (Singapore) Pte. Ltd.

AstraZeneca PLC

70.35
+0.03010.04%
Volume:1.99M
Turnover:139.83M
Market Cap:218.18B
PE:28.31
High:70.69
Open:69.96
Low:69.85
Close:70.32
Loading ...

AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ...

GuruFocus.com
·
30 Apr

AstraZeneca PLC ADR Outperforms Market On Strong Trading Day

Dow Jones
·
30 Apr

Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says

MT Newswires Live
·
30 Apr

Pfizer CEO: 'We should not have tariffs' on pharma

Yahoo Finance
·
30 Apr

AstraZeneca CEO: Trump tariffs 'not material long term'

Yahoo Finance
·
30 Apr

Top Midday Stories: Amazon Says Listing Tariff Pricing Never Considered for Main Site; Novo Nordisk Partners With Hims on Wegovy

MT Newswires
·
29 Apr

Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia

MT Newswires Live
·
29 Apr

AstraZeneca Halts Phase 3 Trial for Prostate Cancer Treatment Combination

MT Newswires Live
·
29 Apr

AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty

Benzinga
·
29 Apr

Earnings Movers | Leggett & Platt Surges 23%; SoFi Jumps 9%; NXP Drops 6%; Spotify Sinks 7%

Tiger Newspress
·
29 Apr

Here's Why Astrazeneca (AZN) is a Strong Value Stock

Zacks
·
29 Apr

Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks
·
29 Apr

AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs

Zacks
·
29 Apr

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

Dow Jones
·
29 Apr

UBS Remains a Buy on AstraZeneca (AZN)

TIPRANKS
·
29 Apr

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

Dow Jones
·
29 Apr

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

Dow Jones
·
29 Apr

AstraZeneca's Q1 Core Earnings, Revenue Rise; Reaffirms 2025 Guidance

MT Newswires Live
·
29 Apr

AstraZeneca PLC reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
29 Apr

AstraZeneca Reaffirms 2025 Guidance: Revenue Growth In High Single-Digit, Core EPS Growth In Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

Benzinga
·
29 Apr